Alnylam Pharmaceuticals Aktie
195,15
EUR
+6,75
EUR
+3,58
%
229,10
USD
+0,38
USD
+0,16
%
Alnylam Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Alnylam Pharmaceuticals Aktie Analyse
| 30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
| 24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
| 26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
| 15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
| 21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
| 10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
| 14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
|
Werbung
|
|||
Werbung
Werbung